CURRICULUM VITAE

A. IDENTIFYING DATA

Name: Mehrdad Shamloo, Ph.D.

EXECUTIVE SUMMARY:

I've worked in the fields of neuropharmacology, neurobehavior, and brain disorders since the inception of my doctoral studies in 1999. Directed, as PI and Co-PI on numerous industrial and NIH-funded research projects in this field and have published this work extensively. I have maintained my laboratory since 2001 in both industry and academic environments. In 2007, I started, managed, and directed the Stanford Behavioral and Functional Neuroscience Laboratory at Stanford University, a platform to conduct experimental behavioral pharmacology studies from start to finish with an assessment of the neuropathological and biochemical endpoints at the molecular and cellular levels. The last ten years, my laboratory has focused on understanding the underlying mechanism behind the pathologies in neurodegenerative and psychiatric disorders to develop therapeutic interventions to improve people's quality of life. As a direct result of the research in my laboratory, there are three ongoing clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease **(**PD). Furthermore, these activities led to the creation of three Stanford-originated Biotech Companies (CuraSen Therapeutics, Evia Therapeutics, and Longieva Therapeutics). I have extensive experience in AD animal modeling, drug discovery, neurobehavior, and neuropharmacology, and I have spent much time studying and publishing this work. My research efforts during these last ten years have led to the development of several neurotherapeutics currently in clinical testing for AD and PD.

A. EMPLOYMENT

2022 – Present	Director, Stanford Program for Integrated Neuroscience Technologies
2017 – Present	Professor, Neurosurgery and Neurology Stanford University School of Medicine
2012 – 2017	Associate Professor, Neurosurgery and Neurology, Stanford University School of Medicine
2008 – 2013	Program Director, Stanford Institute of Neuro-Innovation and Translational Neurosciences (SINTN), Stanford University School of Medicine
2007 – Present	Director, Behavioral and Functional Neuroscience Laboratory, Stanford Neuroscience Institute Stanford University
2005 – 2007	Associate Director, Preclinical Development, Affymax
2003 – 2005	Senior Scientist/Program Leader, Pharmacology, AGY Therapeutics
2001 – 2003	Research Scientist, Target Validation and Identification Group, AGY Therapeutics
1999 – 2001	Associate Scientist, Research Group, AGY Therapeutics
1994 – 1999	PhD Student, PhD Program, Faculty of Medicine, University of Lund, Sweden, Wallenberg Neuroscience Research Center
1992 – 1994	Research Associate, Experimental Brain Research, University of Lund, Sweden

B. ACADEMIC HISTORY

Colleges and Universities Attended

1994 B.S., Malmo College of Health and Science, Sweden

1998 M.S., Medical School, University of Lund, Sweden

1999 Ph.D., Medical Science, Faculty of Medicine, University of Lund, Sweden (Wallenberg Neuroscience Research Center)

Scholarships and Honors

2004 AGY Award for contribution, dedication and high quality preclinical studies

Other Study and Research Opportunities

Present:

*Title: Dietary and Microbial Reprogramming of Intestinal Microbiota-Produced Metabolites
Major Goals: To define the bacterial species and genes that make toxic compounds and determine how the gut microbiota can be rationally altered to reduce the production of toxic substances.

Status of Support: Active
Project Number: R01 DK101674 (SPO 111862)
Name of PD/PI: Sonnenburg, J. (contact PI), Shamloo, M. (MPI)
Source of Support: National Institutes of Health
Project/Proposal Start and End Date: 04/15/2020 – 03/31/2025

*Title: Role of beta-adrenergic receptors in modulation of cognition and central and peripheral immune systems in Alzheimer's disease

Major Goals: The aim of this proposal is to investigate the mechanistic basis of adrenergic receptor subtype tone on cognitive function, CNS resident microglia and infiltrating macrophage function, and recruitment of peripheral immune cells to the brain, to determine mechanisms through which modulation of these receptors can mitigate disease progression and reverse cognitive deficits in AD.

Status of Support: Active
Project Number: R01 AG054533 (SPO 123697)
Name of PD/PI: Shamloo, M.
Source of Support: National Institutes of Health
Primary Place of Performance: Stanford University
Project/Proposal Start and End Date: 08/01/2017 – 05/31/2024

*Title: Neurometabolic Outcomes of Different Cardiopulmonary Bypass Strategies
Major Goals: The aim of this project is to document continuous time-related changes in brain metabolites and correlate altered levels of these metabolites with alterations in cognitive development following DHCA and ACP bypass procedures.

Status of Support: Active
Project Number: R01 HL152757 (SPO 153435)
Name of PD/PI: Hanley, F. (PI), Shamloo, M. (Co-Investigator)
Source of Support: National Institutes of Health
Primary Place of Performance: Stanford University
Project/Proposal Start and End Date: 02/15/2021 – 01/31/2025

*Title: A Shared Neuroscience Platform for National Dissemination and Training in Brain Organogenesis, Behavioral and Brain Disease Models, Viral Vectors, and Imaging Technologies
Major Goals: To fund the Stanford Neurosciences Research Center in order to centralize and disseminate fundamental tools and techniques that are essential for the neuroscience community at the national level.

Status of Support: Active
Project Number: U24NS124026 (SPO 209382)
Name of PD/PI: Shamloo, M.
Source of Support: National Institutes of Health
Primary Place of Performance: Stanford University
Project/Proposal Start and End Date: 06/16/2022-05/31/2027

*Title: CD36-dependent neuroimmune pathway regulates disruption of gut motility in Alzheimer's Disease
Major Goals: The aim is to investigate CD36-dependent neuroimmune pathway regulation disruption of gut motility in Alzheimer's Disease.

Status of Support: Active
Project Number: R21 AG077521 (SPO 231906)
Name of PD/PI: Becker, L. (contact PI), Shamloo, M. (MPI)
Source of Support: National Institutes of Health
Primary Place of Performance: Stanford University
Project/Proposal Start and End Date: 05/15/2022 – 04/30/2024

*Title: Development of selective cannabinoid receptor 2 agonists for treatment of addiction
Major Goals: This project aims to collaborate with the Blueprint Neurotherapeutics Network team for lead optimization of our novel cannabinoid receptor 2 agonists class into preclinical/clinical development for the treatment of methamphetamine use disorder.

Status of Support: Active
Project Number: UH3 NS127382 (SPO 234935)
Name of PD/PI: Shamloo, M.
Source of Support: National Institutes of Health

Primary Place of Performance: Stanford University
Project/Proposal Start and End Date: 05/15/2023-04/30/2027
This is the UH3 phase of the awarded grant UG3 NS127382

*Title: Selective Cannabinoid Receptor 2 Agonists for the Treatment of Parkinson's Disease
Goal: This project aims to test the efficacy of a cannabinoid 2 receptor agonist for the treatment of Parkinson's Disease

Status of Support: Active
Project Number: SPO 258278
Name of PD/PI: Shamloo, M.
Source of Support: Stanford SPARK
Primary Place of Performance: Stanford University
Project/Proposal Start and End Date: 05/01/2022-04/10/2024
This is a University Research Agreement; the PI does not devote a specific amount of effort.

*Title: Altered ENS Neuroimmune Interactions Disrupt Gastrointestinal Motility in Alzheimer's Disease
Major Goals: This project aims to test how altered ENS Neuroimmune interactions disrupts gastrointestinal motility in Alzheimer's disease models.

Status of Support: Active
Project Number: BEC0001-01 / R01 AG068394-03 (SPO 270267)
Name of PD/PI: Becker, L. (PI), Shamloo, M. (Co-Investigator)
Source of Support: Palo Alto Veterans Institute for Research (PAVIR) / National Institutes of Health
Primary Place of Performance: Stanford University
Project/Proposal Start and End Date: 03/01/2023-05/31/2026

*Title: Mechanisms of sleep fragmentation in a mouse model of Alzheimer's disease
Major Goals: Addressing the impact of hyperexcitability of arousal circuits on the development of animal models of Alzheimer's Disease.

Status of Support: Active
Project Number: RF1 AG082202 (SPO 271532)
Name of PD/PI: de Lecea, L. (PI), Shamloo, M. (Co-Investigator)
Source of Support: National Institutes of Health
Primary Place of Performance: Stanford University
Project/Proposal Start and End Date: 04/15/2023-03/31/2026

Collaboration Contracts - Past:

N/A
Source of Support: Stanford – Wu Tsai Neurosciences Institute 02/16/22 – 02/15/23
Title: Development and Validation of Selective Cannabinoid Receptor 2 Agonists for the Treatment of Parkinson's Disease
Role: Principal Investigator

1R56AG06839401 09/15/20 – 05/31/22
National Institutes of Health
Title: Altered ENS Neuroimmune Interactions Disrupt Gastrointestinal Motility in Alzheimer's Disease
Role: Co-Principal Investigator

1U18DA05241501 09/30/20 – 09/29/21
National Institutes of Health
Title: Validation and pharmacological profiling of a non-psychoactive THC analog, a novel and selective CB2 receptor agoinist, in proof of concept studies using rodent models of heroin addiction
Role: Principal Investigator

N/A 04/01/20 – 03/31/21
Stanford - SPARK
Title: Development of novel and selective death-associated protein kinase 1 inhibitors for the treatment of neurodegenerative diseases
Role: Principal Investigator

N/A 04/01/20 – 03/31/21
Stanford - SPARK
Title: A Small-Molecule Activator of AMPK for Treatment of Mitochondrial Disorders
Role: Principal Investigator

5 R01 AG054533 04 (Shamloo, PI) 08/01/17 – 05/31/22
National Institutes of Health
Title: Role of beta adrenergic receptors in modulation of cognition, pathology and neuro inflammation in Alzheimer's disease
Role: Principal Investigator

5 P30 NSO69375 09 03/01/11 – 11/30/20
National Institutes of Health
Title: Stanford Neuroscience Research Cores for Gene Vectors, Microscopy and Behavior. Establish Neuroscience Research Cores: Behavior, Imaging and Gene-Vector CORES.
Role: Co-Principal Investigator

5 R01 DK101674 06A1 04/01/20 - 03/31/25
National Institutes of Health
Title: Dietary and Microbial Reprogramming of Intestinal Microbiota-Produced Metabolites
Role: Co-Principal Investigator

SPARK 05/01/18 – 04/30/19
Title: Development of CNS-biased and selective death-associated protein kinase 1 inhibitors for the treatment of neurodegenerative disease.
Role: Principal Investigator

Denali Therapeutics, Inc. 09/01/16 – 12/31/18
Title: The role of inflammation in neurological disorders.
Role: Principal Investigator (Research-collaboration contract)

R21NS088841 07/01/14 – 06/30/17
National Institutes of Health
Title: Reverse Translation of Patient Controlled Analgesia: A New Measure of Rodent Pan
Role: Co-Principal Investigator

SIP 07/01/16 – 03/31/17
Title: Discovery and development of novel beta-adrenergic receptor ligands as potential therapeutic agents.
Role: Principal Investigator (Research-collaboration contract)

SanBio, Inc. 04/15/15 – 02/28/17
Title: Evaluation of the therapeutic effect of the Mesenchymal stem cells and their mechanism of action in stroke.
Role: Principal Investigator (Research-collaboration contract)

SPECTRUM/SPARK 01/01/15 – 12/31/17
Title: Development of novel adrenergic receptor agonists.
Role: Principal Investigator (Research-collaboration contract)

BioTime, Inc. 07/01/15 – 06/30/17
Title: Establishing In-vivo efficacy of exogenous BDNF in the permanent distal Middle Cerebral Artery Occlusion (dMCAO) rat stroke model and measure post-treatment functional recovery
Role: Principal Investigator (Research-collaboration contract)

Cognition Therapeutics, Inc. 01/01/15 – 01/30/17
Title: Efficacy of Cog-Tx3 and Cog Tx4 in Thy1-APPLond/Swe mouse model for Alzheimer's disease
Role: Principal Investigator (Research-collaboration contract)

Adamas Pharmaceuticals, Inc. 07/01/15 – 06/30/17
Title: Effect of Amantadine on Functional Recovery in experimental model of ischemic stroke.
Role: Principal Investigator (Research-collaboration contract)

P01AG036695 07/01/11– 06/30/17
National Institutes of Health
Title: Molecular Regulation of Stem Cell Aging
Role: Principal Investigator

SanBio, Inc. 02/01/15 – 02/29/16
Title: Evaluation of the therapeutic effect of the Mesenchymal stem cells and their mechanism of action in stroke.
Role: Principal Investigator (Research-collaboration contract)

Omniox 02/04/15 – 12/31/15
Title: Testing efficacy of Omniox-TX compound in a MCAO model of stroke.
Role: Principal Investigator (Research-collaboration contract)

ViroBay 10/03/13 – 10/03/14
Title: Effects of Cathepsin S Inhibitor in the SOD1 Mouse Model of Amyotrophic Lateral Sclerosis (ALS) and Alzheimer disease (AD).
Role: Principal Investigator (Research-collaboration contract)

J. David Gladstone Institutes 09/01/13 – 08/31/14
Title: Inhibiting Tau Acetylation to Treat Tauopathy – Supplement.
Role: Principal Investigator (Research-collaboration contract)

California Institute of Regenerative Medicine 02/01/10 – 01/31/14
Title: Embryonic-Derived Neural Stem Cells for Treatment of Motor Sequelae following Sub-cortical Stroke.
Role: Co-Principal Investigator

Simons Foundation 10/01/10 – 09/30/13
Title: Function and Dysfunction of Neuroligins in Synaptic Circuits.
Role: Co-Principal Investigator

Cognition Therapeutics 07/01/12 – 01/30/14
Title: Does Treatment with CT013461 Rescue Cognitive Deficit in the Thy1-APPLond/Swe Mouse Model of Alzheimer's Disease.
Role: Principal Investigator (Research-collaboration contract)

Applied StemCell 08/01/10 – 09/30/12
Title: Engraftment of human somatic and stem cell expressing an immune tolerance gene.
Role: Principal Investigator (Research-collaboration contract)

Coyote Pharmaceutical 12/01/10 – 05/31/12
Title: Testing the Effects of CNS-102 in the SOD1 Mouse Model of Amyotrophic Lateral Sclerosis.
Role: Principal Investigator (Research-collaboration contract)

Genentech 11/01/10 – 01/31/11
Title: Does reducing inhibition by antagonizing the NR2B subunit of the NMDA receptor rescue cognitive deficits in the Tg65Dn mouse model of Down's syndrome.
Role: Principal Investigator (Research-collaboration contract)

Genentech 09/01/09 – 08/31/11
Title: Does Removal of DR6 Alter Behavior or Pathology in Mice over Expressing Human APP.
Role: Principal Investigator (Research-collaboration contract)

Élan Pharmaceutical 11/01/09 – 03/31/10
Title: Behavioral outcome and pathology in PDAPP mice model of Alzheimer's disease.
Role: Principal Investigator (Research-collaboration contract)

C. PUBLIC AND PROFESSIONAL SERVICE

2023 – Present	Founder, Longieva Therapeutics
2021 – Present	Founder, Evia Therapeutics
2019 – Present	Member Student Advisor Board, Stanford University
2018 – Present	Founder, Curasen Therapeutics
2015 – Present	Member, Stanford Neurosciences Institute
2015 – Present	Advisor and member of advisory board SPARK Stanford University
2014 – Present	Member, Bio-X Stanford University
2011 – Present	Member, School of Medicine Cores Advisory Board, Stanford University
2010 – Present	Faculty advisor, member of advisory board of Gene Vector
2010 – Present	Faculty advisor, member of advisory board of Neuroscience Microscopy
2010 – Present	Member, SIM-1 Advisory Committee, School of Medicine Stanford University
2007 – 2013	Member, Institutional Animal Care and Use Committee, Palo Alto Medical Foundation
2007 – 2013	Member, Executive Committee, Stanford Institute for Neuro-Innovation and Translational Neurosciences, Stanford University School of Medicine
2007 – 2013	Program Director, Stanford Institute for Neuro-Innovation and Translational Neurosciences, Stanford University School of Medicine
2007 – 2013	Director of Pharmacology & Toxicology, CIRM Disease Team Stroke Neural Transplant Program, Stanford University School of Medicine

Consulting Positions:

2011 – 2014	Pharmacology and Behavior consultant, Weizmann Institute of Science
2011 – 2014	Pharmacology and Behavior consultant, Durham Research Center, University of Nebraska Medical Center
2011 – 2012	Pharmacology consultant, University of California, Irvine
2010 – 2012	Pharmacology and Behavior consultant, Institute for Neurodegenerative Diseases, University of California, San Francisco
2010 – 2012	Pharmacology consultant, University of California, San Diego, Translational Neuroscience Institute
2010 – 2012	Pharmacology consultant, Scripps Research Institute

Editorial Positions:

2014 – Present	Editorial Board Member, *Journal of Neurocardiovascular Disease*
2012 – Present	Editorial Board Member, *ISRN Stroke (International Scholarly Research Network)*
2011 – Present	Editorial Consultant, *Journal of Neuroscience*
2006 – Present	Editorial Consultant, *Journal of Biological Chemistry*

2006 – Present	Editorial Consultant, *Journal of Neurochemistry*
2004 – Present	Editorial Consultant, *Annals of Neurology*
2004 – Present	Editorial Consultant, *Life Sciences*
2000 – Present	Editorial Consultant, *Brain Research Protocols*
2000 – Present	Editorial Consultant, *Brain Research*
2000 – Present	Editorial Consultant, *Brain Research Reviews*

Advisory Positions:

2016 – Present	Member of the Scientific Advisory Board Sensoplex
2014 – Present	Member of the Scientific Advisory Board Cortice Biosciences
2011 – Present	Scientific Advisor Cognition Therapeutics
2008 – Present	Pharmacology Consultant, Affymax
2008 – Present	Preclinical and Pharmacology Consultant, Genyous
2008 – Present	Preclinical and Pharmacology Consultant, Omnitura
2008 – Present	Preclinical and Pharmacology Consultant, Vitala
2007 – 2012	Pharmacology Consultant, KAI Pharmaceutical
2005 – 2010	Pharmacology Consultant, AGY Therapeutics

D. POST-DEGREE HONORS AND AWARDS, INCLUDING MEMBERSHIPS IN PROFESSIONAL SOCIETIES

2019 – Present	Member, American Society for Pharmacology and Experimental Therapeutics (ASPET)
2018 – Present	Member, International Society for Cerebral Blood Flow & Metabolism (ISCBFM)
2014 – Present	Member, Fellow, American Neurological Association (ANA)
2008 – Present	Member, International Behavioral Neuroscience Society (IBNS)
2008 – Present	Member, International Brain Organization (IBRO)
1997 – Present	Member, Society for Neuroscience (SfN)

E. BIBLIOGRAPHY

Pending Articles:

In Preparation

1. DAPK1 project Discovery of selective DAPK1 inhibitors and their therapeutic implications in neurological disorders. Matteo Santoro, Alex Ferris, Rachel K. Lam, Claire E. Woods, Peter Ciari, Michael J. Green, Alam Jahangir, Denise Briggs, Mehrdad Shamloo

2. 6-OHDA Parkinson's mouse model Time course characterization of three 6-OHDA striatal mouse models of Parkinson's disease, NR2B and DAPK1 cell signaling pathway and immunological response. Matteo Santoro, Rachel K. Lam, Sarah Blumenfeld Peter Ciari, Emily Chu, Angela Tan, Nay L. Saw, Daniel Ryskamp, Mehrdad Shamloo.

3. SARS-CoV-2 S1
   Spike protein induces neuroinflammation in mice: a temporal profile of systemic and central cytokine expression. E. B. Defensor, E. Chu, C. E. Woods, S. E. Blumenfeld, S. Falsafi, R. K. Lam, P. Ciari, W. Tan, A. E. Barron, M. Shamloo.

For submission
to *Neurobiology of Disease*
Working title: Effects of chemogenetic, pharmacological and genetic modulation of the noradrenergic system on pathology and behavior in mouse models of AD
Andrew K. Evans, Heui Hye Park, Emily Chu, Peter Ciari, Claire Woods, Nay Lui Saw, and Mehrdad Shamloo

ADRB1 selective agonists - Ready to be submitted to Bioorganic & Medicinal Chemistry Letters Functionally Selective Novel Ligands of Beta-Adrenergic Receptors.
Matteo Santoro, Jennifer S. Lin, Alam Jahangir, Michael Green, Bitna Yi, Andrew K. Evans, Kristine Ravina, Jacqueline Ernest, Matthew Klope, Jeyakannu Palaniraja, and Mehrdad Shamloo

Publications:

1. Andrew K. Evans, Laura M. Vidano, Claire E. Woods, Nay L. Saw, Rachel K. Lam, Emily K. Chu Chris Reading, and Mehrdad Shamloo. High-fat diet induces anxiety, impairs learning and memory, and potentiates systemic inflammation and neuroinflammation in aged male mice. Brain behavior and Immunity. 2024 February; doi: 10.1016/j.bbi.2024.02.025. PMID: 38408498

2. Evans AK, Defensor E, Shamloo M. Selective Vulnerability of the Locus Coeruleus Noradrenergic System and its Role in Modulation of Neuroinflammation, Cognition, and Neurodegeneration. Front Pharmacol. 2022 Nov 30; 13:1030609. doi:10.3389/fphar.2022.1030609. PMID: 36532725; PMCID: PMC9748190.

3. Revah O, Gore F, Kelley KW, Andersen J, Sakai N, Chen X, Li MY, Birey F, Yang X, Saw NL, Baker SW, Amin ND, Kulkarni S, Mudipalli R, Cui B, Nishino S, Grant GA, Knowles JK, Shamloo M, Huguenard JR, Deisseroth K, Pașca SP. Maturation and circuit integration of transplanted human cortical organoids. Nature. 2022 Oct;610(7931):319-326. doi: 10.1038/s41586-022-05277-w. Epub 2022 Oct 12. PMID: 36224417; PMCID: PMC9556304.

4. Aloul KM, Nielsen JE, Defensor EB, Lin JS, Fortkort JA, Shamloo M, Cirillo JD, Gombart AF, Barron AE. Upregulating Human Cathelicidin Antimicrobial Peptide LL-37 Expression May Prevent Severe COVID-19 Inflammatory Responses and Reduce Microthrombosis. Front Immunol. 2022 May 12;13:880961. doi: 10.3389/fimmu.2022.880961. PMID: 35634307; PMCID: PMC9134243.

5. Lam DD, Williams RH, Lujan E, Tanabe K, Huber G, Saw NL, Merl-Pham J, Salminen AV, Lohse D, Spendiff S, Plastini MJ, Zech M, Lochmüller H, Geerlof A, Hauck SM,

Shamloo M, Wernig M, Winkelmann J. Collagen VI Regulates Motor Circuit Plasticity and Motor Performance by Cannabinoid Modulation. J Neurosci. 2022 Feb 23;42(8):1557-1573. doi: 10.1523/JNEUROSCI.0962-21.2021. Epub 2021 Dec 27. PMID: 34965974; PMCID: PMC8883874.

6. De Miguel Z, Khoury N, Betley MJ, Lehallier B, Willoughby D, Olsson N, Yang AC, Hahn O, Lu N, Vest RT, Bonanno LN, Yerra L, Zhang L, Saw NL, Fairchild JK, Lee D, Zhang H, McAlpine PL, Contrepois K, Shamloo M, Elias JE, Rando TA, Wyss- Coray T. Exercise plasma boosts memory and dampens brain inflammation via clusterin. Nature. 2021 Dec;600(7889):494-499. doi: 10.1038/s41586-021-04183-x. Epub 2021 Dec 8. PMID: 34880498; PMCID: PMC9721468.

7. Evans AK, Park HH, Saw NL, Singhal K, Ogawa G, Leib RD, Shamloo M. Age-related neuroinflammation and pathology in the locus coeruleus and hippocampus: beta-adrenergic antagonists exacerbate impairment of learning and memory in aged mice. Neurobiol Aging. 2021 Oct;106:241-256. doi: 10.1016/j.neurobiolaging.2021.06.012. Epub 2021 Jun 20. PMID: 34320462; PMCID: PMC8419102.

8. Wawro AM, Gajera CR, Baker SA, Leśniak RK, Montine KS, Fischer CR, Saw NL, Shamloo M, Montine TJ. Enantiomers of 4-aminopentanoic acid act as false GABAergic neurotransmitters and impact mouse behavior. J Neurochem. 2021 Sep;158(5):1074-1082. doi: 10.1111/jnc.15474. Epub 2021 Aug 2. PMID: 34273193.

9. Wawro AM, Gajera CR, Baker SA, Leśniak RK, Fischer CR, Saw NL, Shamloo M, Montine TJ. Enantiomers of 2-methylglutamate and 2-methylglutamine selectively impact mouse brain metabolism and behavior. Sci Rep. 2021 Apr 14;11(1):8138. doi: 10.1038/s41598-021-87569-1. PMID: 33854131; PMCID: PMC8047011.

10. Evans AK, Ardestani PM, Yi B, Park HH, Lam RK, Shamloo M. Beta-adrenergic receptor antagonism is proinflammatory and exacerbates neuroinflammation in a mouse model of Alzheimer's Disease. Neurobiol Dis.2020 Dec;146:105089. doi: 10.1016/j.nbd.2020.105089. Epub 2020 Sep 22. PMID: 32971233; PMCID: PMC7686098.

11. Tsai RM, Miller Z, Koestler M, Rojas JC, Ljubenkov PA, Rosen HJ, Rabinovici GD, Fagan AM, Cobigo Y,b Brown JA, Jung JI, Hare E, Geldmacher DS, Natelson-Love M, McKinley EC, Luong PN, Chuu EL, Powers R, Mumford P, Wolf A, Wang P, Shamloo M, Miller BL, Roberson ED, Boxer AL. Reactions to Multiple Ascending Doses of the Microtubule Stabilizer TPI-287 in Patients With Alzheimer Disease, Progressive Supranuclear Palsy, and Corticobasal Syndrome: A Randomized Clinical Trial. JAMA Neurol. 2020 Feb 1;77(2):215-224. doi: 10.1001/jamaneurol.2019.3812. PMID: 31710340; PMCID: PMC6865783.

12. Liu Q, Johnson EM, Lam RK, Wang Q, Bo Ye H, Wilson EN, Minhas PS, Liu L, Swarovski MS, Tran S, Wang J, Mehta SS, Yang X, Rabinowitz JD, Yang SS, Shamloo M, Mueller C, James ML, Andreasson KI. Peripheral TREM1 responses to brain and

intestinal immunogens amplify stroke severity. Nat Immunol. 2019 Aug;20(8):1023 1034. doi: 10.1038/s41590-019-0421-2. Epub 2019 Jul 1. PMID: 31263278; PMCID: PMC6778967.

13. Liu Q, Liang X, Wang Q, Wilson EN, Lam R, Wang J, Kong W, Tsai C, Pan T, Larkin PB, Shamloo M, Andreasson KI. PGE2 signaling via the neuronal EP2 receptor increases injury in a model of cerebral ischemia. Proc Natl Acad Sci U S A. 2019 May 14;116(20):10019-10024. doi: 10.1073/pnas.1818544116. Epub 2019 Apr 29. PMID: 31036664; PMCID: PMC6525498.

14. Bieri G, Brahic M, Bousset L, Couthouis J, Kramer NJ, Ma R, Nakayama L, Monbureau M, Defensor E, Schüle B, Shamloo M, Melki R, Gitler AD. LRRK2 modifies α-syn pathology and spread in mouse models and human neurons. Acta Neuropathol. 2019 Jun;137(6):961-980. doi: 10.1007/s00401-019-01995-0. Epub 2019 Mar 29. PMID: 30927072; PMCID: PMC6531417.

15. Ravina K, Briggs DI, Kislal S, Warraich Z, Nguyen T, Lam RK, Zarembinski TI, Shamloo M. Intracerebral Delivery of Brain-Derived Neurotrophic Factor Using HyStem®-C Hydrogel Implants Improves Functional Recovery and Reduces Neuroinflammation in a Rat Model of Ischemic Stroke. Int J Mol Sci. 2018 Nov 28;19(12):3782. doi: 10.3390/ijms19123782. PMID: 30486515; PMCID: PMC6321015.

16. Huang WH, Wang DC, Allen WE, Klope M, Hu H, Shamloo M, Luo L. Early adolescent Rai1 reactivation reverses transcriptional and social interaction deficits in a mouse model of Smith-Magenis syndrome. Proc Natl Acad Sci U S A. 2018 Oct 16;115(42):10744-10749. doi: 10.1073/pnas.1806796115. Epub 2018 Oct 1.PMID: 30275311; PMCID: PMC6196530.

17. Kornfeld OS, Qvit N, Haileselassie B, Shamloo M, Bernardi P, Mochly-Rosen D. Interaction of mitochondrial fission factor with dynamin related protein 1 governs physiological mitochondrial function in vivo. Sci Rep. 2018 Sep 19;8(1):14034. doi: 10.1038/s41598-018-32228-1. PMID: 30232469; PMCID:PMC6145916.

18. Djurisic M, Brott BK, Saw NL, Shamloo M, Shatz CJ. Activity-dependent modulation of hippocampal synaptic plasticity via PirB and endocannabinoids. Mol Psychiatry. 2019 Aug;24(8):1206-1219. doi: 10.1038/s41380-018 0034-4. Epub 2018 Apr 18. PMID: 29670176; PMCID: PMC6372352.

19. Joshi AU, Saw NL, Shamloo M, Mochly-Rosen D. Drp1/Fis1 interaction mediates mitochondrial dysfunction, bioenergetic failure and cognitive decline in Alzheimer's disease. Oncotarget. 2017 Dec 22;9(5):6128-6143. doi: 10.18632/oncotarget.23640. PMID: 29464060; PMCID: PMC5814200.

20. Joshi AU, Saw NL, Vogel H, Cunnigham AD, Shamloo M, Mochly-Rosen D. Inhibition of Drp1/Fis1 interaction slows progression of amyotrophic lateral sclerosis. EMBO Mol

Med. 2018 Mar;10(3):e8166. doi: 10.15252/emmm.201708166. PMID: 29335339; PMCID: PMC5840540.

21. Sha SJ, Miller ZA, Min SW, Zhou Y, Brown J, Mitic LL, Karydas A, Koestler M, Tsai R, Corbetta-Rastelli C, Lin S, Hare E, Fields S, Fleischmann KE, Powers R, Fitch R, Martens LH, Shamloo M, Fagan AM, Farese RV Jr, Pearlman R, Seeley W, Miller BL, Gan L, Boxer AL. An 8-week, open-label, dose-finding study of nimodipine for the treatment of progranulin insufficiency from GRN gene mutations. Alzheimers Dement (N Y). 2017 Sep 12;3(4):507-512. doi: 10.1016/j.trci.2017.08.002. PMID: 29124108; PMCID: PMC5671622.

22. Yi B, Jahangir A, Evans AK, Briggs D, Ravina K, Ernest J, Farimani AB, Sun W, Rajadas J, Green M, Feinberg EN, Pande VS, Shamloo M. Discovery of novel brain permeable and G protein-biased beta-1 adrenergic receptor partial agonists for the treatment of neurocognitive disorders. PLoS One. 2017 Jul 26;12(7):e0180319. doi:10.1371/journal.pone.0180319. PMID: 28746336; PMCID: PMC5529018.

23. Briggs DI, Defensor E, Memar Ardestani P, Yi B, Halpain M, Seabrook G, Shamloo M. Role of Endoplasmic Reticulum Stress in Learning and Memory Impairment and Alzheimer's Disease-Like Neuropathology in the PS19 and APP Swe Mouse Models of Tauopathy and Amyloidosis. eNeuro. 2017 Jul 14;4(4):ENEURO.0025-17.2017. doi: 10.1523/ENEURO.0025-17.2017. PMID: 28721361; PMCID: PMC5510086.

24. Simmons DA, Belichenko NP, Ford EC, Semaan S, Monbureau M, Aiyaswamy S, Holman CM, Condon C, Shamloo M, Massa SM, Longo FM. A small molecule p75NTR ligand normalizes signalling and reduces Huntington's disease phenotypes in R6/2 and BACHD mice. Hum Mol Genet. 2016 Nov 15;25(22):4920-4938. doi:10.1093/hmg/ddw316. PMID: 28171570; PMCID: PMC5418739.

25. Ardestani PM, Evans AK, Yi B, Nguyen T, Coutellier L, Shamloo M. Modulation of neuroinflammation and pathology in the 5XFAD mouse model of Alzheimer's disease using a biased and selective beta-1 adrenergic receptor partial agonist. Neuropharmacology. 2017 Apr;116:371-386. doi: 10.1016/j.neuropharm.2017.01.010. Epub 2017 Jan 13. PMID: 28089846; PMCID: PMC5385159.

26. Yi B, Sahn JJ, Ardestani PM, Evans AK, Scott LL, Chan JZ, Iyer S, Crisp A, Zuniga G, Pierce JT, Martin SF, Shamloo M. Small molecule modulator of sigma 2 receptor is neuroprotective and reduces cognitive deficits and neuroinflammation in experimental models of Alzheimer's disease. J Neurochem. 2017 Feb;140(4):561-575. doi: 10.1111/jnc.13917. PMID: 27926996; PMCID: PMC5312682.

27. Disatnik MH, Joshi AU, Saw NL, Shamloo M, Leavitt BR, Qi X, Mochly-Rosen D. Potential biomarkers to follow the progression and treatment response of Huntington's disease. J Exp Med. 2016 Nov 14;213(12):2655-2669. doi: 10.1084/jem.20160776. Epub 2016 Nov 7. PMID: 27821553; PMCID: PMC5110026.

28. Huang WH, Guenthner CJ, Xu J, Nguyen T, Schwarz LA, Wilkinson AW, Gozani O, Chang HY, Shamloo M, Luo] L. Molecular and Neural Functions of Rai1, the Causal Gene for Smith-Magenis Syndrome. Neuron. 2016 Oct 19;92(2):392-406. doi:10.1016/j.neuron.2016.09.019. Epub 2016 Sep 29. PMID: 27693255; PMCID: PMC5098476.

29. Kiss K, Csonka C, Pálóczi J, Pipis J, Görbe A, Kocsis GF, Murlasits Z, Sárközy M, Szűcs G, Holmes CP, Pan Y, Bhandari A, Csont T, Shamloo M, Woodburn KW, Ferdinandy P, Bencsik P. Novel, selective EPO receptor ligands lacking erythropoietic activity reduce infarct size in acute myocardial infarction in rats. Pharmacol Res. 2016 Nov;113(Pt A):62-70. doi: 10.1016/j.phrs.2016.08.013.Epub 2016 Aug 10. PMID: 27521836.

30. Min SW, Chen X, Tracy TE, Li Y, Zhou Y, Wang C, Shirakawa K, Minami SS, Defensor E, Mok SA, Sohn PD, Schilling B, Cong X, Ellerby L, Gibson BW, Johnson J, Krogan N, Shamloo M, Gestwicki J, Masliah E, Verdin E, Gan L. Critical role of acetylation in tau-mediated neurodegeneration and cognitive deficits. Nat Med. 2015 Oct;21(10):1154-62. doi: 10.1038/nm.3951. Epub 2015 Sep 21. PMID: 26390242; PMCID: PMC4598295.

31. Izzo NJ, Staniszewski A, To L, Fa M, Teich AF, Saeed F, Wostein H, Walko T 3rd, Vaswani A, Wardius M, Syed Z, Ravenscroft J, Mozzoni K, Silky C, Rehak C, Yurko R, Finn P, Look G, Rishton G, Safferstein H, Miller M, Johanson C, Stopa E, Windisch M, Hutter-Paier B, Shamloo M, Arancio O, LeVine H 3rd, Cat M, Arancio O, LeVine H 3rd, Catalano SM. Alzheimer's therapeutics targeting amyloid beta 1-42 oligomers I: Abeta 42 oligomer binding to specific neuronal receptors is displaced by drug candidates that improve cognitive deficits. PLoS One. 2014 Nov 12;9(11):e111898. doi: 10.1371/journal.pone.0111898. PMID: 25390368; PMCID: PMC4229098.

32. Nguyen TV, Shen L, Vander Griend L, Quach LN, Belichenko NP, Saw N, Yang T,nShamloo M, Wyss-Coray T, Massa SM, Longo FM. Small molecule p75NTR ligands reduce pathological phosphorylation and misfolding of tau, inflammatory changes,cholinergic degeneration, and cognitive deficits in AβPP(L/S) transgenic mice. J Alzheimers Dis. 2014;42(2):459-83. doi: 10.3233/JAD-140036. PMID: 24898660; PMCID: PMC4278429.

33. Coutellier L, Ardestani PM, Shamloo M. β1-adrenergic receptor activation enhances memory in Alzheimer's disease model. Ann Clin Transl Neurol. 2014 May 1;1(5):348-360. doi: 10.1002/acn3.57. PMID: 24883337; PMCID: PMC4036739.

34. Kallop DY, Meilandt WJ, Gogineni A, Easley-Neal C, Wu T, Jubb AM, Yaylaoglu M, Shamloo M, Tessier-Lavigne M, Scearce-Levie K, Weimer RM. A death receptor 6-amyloid precursor protein pathway regulates synapse density in the mature CNS but does not contribute to Alzheimer's disease-related pathophysiology in murine models. J Neurosci. 2014 May 7;34(19):6425-37. doi: 10.1523/JNEUROSCI.4963-13.2014. PMID: 24806669; PMCID: PMC6608138.

35. Portmann T, Yang M, Mao R, Panagiotakos G, Ellegood J, Dolen G, Bader PL, Grueter BA, Goold C, Fisher E, Clifford K, Rengarajan P, Kalikhman D, Loureiro D, Saw NL, Zhengqui Z, Miller MA, Lerch JP, Henkelman M, Shamloo M, Malenka RC, Crawley JN, Dolmetsch RE. Behavioral abnormalities and circuit defects in the basal ganglia of a mouse model of 16p11.2 deletion syndrome. Cell Rep. 2014 May 22;7(4):1077-1092. doi: 10.1016/j.celrep.2014.03.036. Epub 2014 May 1. PMID: 24794428; PMCID: PMC4251471.

36. Simmons DA, Belichenko NP, Yang T, Condon C, Monbureau M, Shamloo M, Jing D, Massa SM, Longo FM. A small molecule TrkB ligand reduces motor impairment and neuropathology in R6/2 and BACHD mouse models of Huntington's disease. J Neurosci. 2013 Nov 27;33(48):18712-27. doi: 10.1523/JNEUROSCI.1310-13.2013. Erratum in: J Neurosci. 2014 Jan 29;34(5):2012. PMID: 24285878; PMCID: PMC3841443.

37. Guo X, Disatnik MH, Monbureau M, Shamloo M, Mochly-Rosen D, Qi X. Inhibition of mitochondrial fragmentation diminishes Huntington's disease-associated neurodegeneration. J Clin Invest. 2013 Dec;123(12):5371-88. doi: 10.1172/JCI70911. Epub 2013 Nov 15. PMID: 24231356; PMCID: PMC3859413.

38. Stephan AH, Madison DV, Mateos JM, Fraser DA, Lovelett EA, Coutellier L, Kim L, Tsai HH, Huang EJ, Rowitch DH, Berns DS, Tenner AJ, Shamloo M, Barres BA. A dramatic increase of C1q protein in the CNS during normal aging. J Neurosci. 2013 Aug 14;33(33):13460-74. doi: 10.1523/JNEUROSCI.1333-13.2013. PMID: 23946404; PMCID: PMC3742932.

39. Beraki S, Litrus L, Soriano L, Monbureau M, To LK, Braithwaite SP, Nikolich K, Urfer R, Oksenberg D, Shamloo M. A pharmacological screening approach for discovery of neuroprotective compounds in ischemic stroke. PLoS One. 2013 Jul 18;8(7):e69233. doi: 10.1371/journal.pone.0069233. PMID: 23874920; PMCID: PMC3715457.

40. Hanson JE, Weber M, Meilandt WJ, Wu T, Luu T, Deng L, Shamloo M, Sheng M, Scearce-Levie K, Zhou Q. GluN2B antagonism affects interneurons and leads to immediate and persistent changes in synaptic plasticity, oscillations, and behavior. Neuropsychopharmacology. 2013 Jun;38(7):1221-33. doi:10.1038/npp.2013.19. Epub 2013 Jan 22. PMID: 23340518; PMCID: PMC3656364.

41. Salih DA, Rashid AJ, Colas D, de la Torre-Ubieta L, Zhu RP, Morgan AA, Santo EE, Ucar D, Devarajan K, Cole CJ, Madison DV, Shamloo M, Butte AJ, Bonni A, Josselyn SA, Brunet A. FoxO6 regulates memory consolidation and synaptic function. Genes Dev. 2012 Dec 15;26(24):2780-801. doi: 10.1101/gad.208926.112. Epub 2012 Dec 7. PMID: 23222102; PMCID: PMC3533081.

42. Pollak J, Doyle KP, Mamer L, Shamloo M, Buckwalter MS. Stratification substantially reduces behavioral variability in the hypoxic-ischemic stroke model. Brain Behav. 2012 Sep;2(5):698-706. doi: 10.1002/brb3.77. Epub 2012 Jul 16. PMID: 23139913; PMCID: PMC3489820.

43. Coutellier L, Beraki S, Ardestani PM, Saw NL, Shamloo M. Npas4: a neuronal transcription factor with a key role in social and cognitive functions relevant to developmental disorders. PLoS One. 2012;7(9):e46604. doi: 10.1371/journal.pone.0046604. Epub 2012 Sep 28. PMID: 23029555; PMCID: PMC3460929.

44. Kleschevnikov AM, Belichenko PV, Faizi M, Jacobs LF, Htun K, Shamloo M, Mobley WC. Deficits in cognition and synaptic plasticity in a mouse model of Down syndrome ameliorated by GABAB receptor antagonists. J Neurosci. 2012 Jul 4;32(27):9217-27. doi: 10.1523/JNEUROSCI.1673-12.2012. PMID: 22764230; PMCID: PMC3411326.

45. Faizi M, Bader PL, Saw N, Nguyen TV, Beraki S, Wyss-Coray T, Longo FM, Shamloo M. Thy1 hAPP(Lond/Swe+) mouse model of Alzheimer's disease displays broad behavioral deficits in sensorimotor, cognitive and social function. Brain Behav. 2012 Mar;2(2):142-54. doi: 10.1002/brb3.41. PMID: 22574282; PMCID:PMC3345358.

46. Wang Q, Rozelle AL, Lepus CM, Scanzello CR, Song JJ, Larsen DM, Crish JF, Bebek G, Ritter SY, Lindstrom TM, Hwang I, Wong HH, Punzi L, Encarnacion A, Shamloo M, Goodman SB, Wyss-Coray T, Goldring SR, Banda NK, Thurman JM, Gobezie R, Crow MK, Holers VM, Lee DM, Robinson WH. Identification of a central role for complement in osteoarthritis. Nat Med. 2011 Nov 6;17(12):1674-9. doi: 10.1038/nm.2543. PMID: 22057346; PMCID: PMC3257059.

47. Bader PL, Faizi M, Kim LH, Owen SF, Tadross MR, Alfa RW, Bett GC, Tsien RW, Rasmusson RL, Shamloo M. Mouse model of Timothy syndrome recapitulates triad of autistic traits. Proc Natl Acad Sci U S A. 2011 Sep 13;108(37):15432-7. doi: 10.1073/pnas.1112667108. Epub 2011 Aug 30. PMID: 21878566; PMCID: PMC3174658.

48. Etherton M, Földy C, Sharma M, Tabuchi K, Liu X, Shamloo M, Malenka RC, Südhof TC. Autism-linked neuroligin-3 R451C mutation differentially alters hippocampal and cortical synaptic function. Proc Natl Acad Sci U S A. 2011 Aug 16;108(33):13764-9. doi: 10.1073/pnas.1111093108. Epub 2011 Aug 1. PMID:21808020; PMCID: PMC3158170.

49. Horie N, Pereira MP, Niizuma K, Sun G, Keren-Gill H, Encarnacion A, Shamloo M, Hamilton SA, Jiang K, Huhn S, Palmer TD, Bliss TM, Steinberg GK. Transplanted stem cell-secreted vascular endothelial growth factor effects poststroke recovery, inflammation, and vascular repair. Stem Cells. 2011 Feb;29(2):274-85. doi: 10.1002/stem.584. PMID: 21732485; PMCID: PMC3524414.

50. Faizi M, Bader PL, Tun C, Encarnacion A, Kleschevnikov A, Belichenko P, Saw N, Priestley M, Tsien RW, Mobley WC, Shamloo M. Comprehensive behavioral phenotyping of Ts65Dn mouse model of Down syndrome: activation of β1-adrenergic receptor by xamoterol as a potential cognitive enhancer. Neurobiol Dis. 2011 Aug;43(2):397-413. doi: 10.1016/j.nbd.2011.04.011. Epub 2011 Apr 17. PMID:21527343; PMCID: PMC3539757.

51. Lan WC, Priestley M, Mayoral SR, Tian L, Shamloo M, Penn AA. Sex-specific cognitive deficits and regional brain volume loss in mice exposed to chronic, sublethal hypoxia. Pediatr Res. 2011 Jul;70(1):15-20. doi: 10.1203/PDR.0b013e31821b98a3. PMID: 21436761; PMCID: PMC3547599.

52. Ruscher K, Shamloo M, Rickhag M, Ladunga I, Soriano L, Gisselsson L, Toresson H, Ruslim-Litrus L, Oksenberg D, Urfer R, Johansson BB, Nikolich K, Wieloch T. The sigma-1 receptor enhances brain plasticity and functional recovery after experimental stroke. Brain. 2011 Mar;134(Pt 3):732-46. doi:10.1093/brain/awq367. Epub 2011 Jan 28. PMID: 21278085.

53. Encarnacion A, Horie N, Keren-Gill H, Bliss TM, Steinberg GK, Shamloo M. Long-term behavioral assessment of function in an experimental model for ischemic stroke. J Neurosci Methods. 2011 Mar 30;196(2):247-57. doi: 10.1016/j.jneumeth.2011.01.010. Epub 2011 Jan 21. PMID: 21256866; PMCID:PMC3539723.

54. Salehi A, Faizi M, Colas D, Valletta J, Laguna J, Takimoto-Kimura R, Kleschevnikov A, Wagner SL, Aisen P, Shamloo M, Mobley WC. Restoration of norepinephrine-modulated contextual memory in a mouse model of Down syndrome. Sci Transl Med. 2009 Nov 18;1(7):7ra17. doi: 10.1126/scitranslmed.3000258. PMID: 20368182.

55. Ishizaki T, Erickson A, Kuric E, Shamloo M, Hara-Nishimura I, Inácio AR, Wieloch T, Ruscher K. The asparaginyl endopeptidase legumain after experimental stroke. J Cereb Blood Flow Metab. 2010 Oct;30(10):1756-66. doi:10.1038/jcbfm.2010.39. Epub 2010 Mar 17. PMID: 20234379; PMCID: PMC3023405.

56. Datwani A, McConnell MJ, Kanold PO, Micheva KD, Busse B, Shamloo M, Smith SJ, Shatz CJ. Classical MHCI molecules regulate retinogeniculate refinement and limit ocular dominance plasticity. Neuron. 2009 Nov 25;64(4):463-70. doi:10.1016/j.neuron.2009.10.015. PMID: 19945389; PMCID: PMC2787480.

57. Braithwaite SP, Xu J, Leung J, Urfer R, Nikolich K, Oksenberg D, Lombroso PJ, Shamloo M. Expression and function of striatal enriched protein tyrosine phosphatase is profoundly altered in cerebral ischemia. Eur J Neurosci. 2008 May;27(9):2444-52. doi: 10.1111/j.1460-9568.2008.06209.x. PMID: 18445231; PMCID: PMC2738830.

58. Shamloo M, Soriano L, von Schack D, Rickhag M, Chin DJ, Gonzalez-Zulueta M, Gido G, Urfer R, Wieloch T, Nikolich K. Npas4, a novel helix-loop-helix PAS domain protein, is regulated in response to cerebral ischemia. Eur J Neurosci.2006 Nov;24(10):2705-20. doi: 10.1111/j.1460-9568.2006.05172.x. PMID: 17156197.

59. Rickhag M, Wieloch T, Gidö G, Elmér E, Krogh M, Murray J, Lohr S, Bitter H, Chin DJ, von Schack D, Shamloo M, Nikolich K. Comprehensive regional and temporal gene expression profiling of the rat brain during the first 24 h after experimental stroke identifies dynamic ischemia-induced gene expression patterns, and reveals a biphasic activation of

genes in surviving tissue. J Neurochem. 2006 Jan;96(1):14-29. doi: 10.1111/j.1471-4159.2005.03508.x. Epub 2005 Nov 21. PMID: 16300643.

60. Shamloo M, Soriano L, Wieloch T, Nikolich K, Urfer R, Oksenberg D. Death-associated protein kinase is activated by dephosphorylation in response tocerebral ischemia. J Biol Chem. 2005 Dec 23;280(51):42290-9. doi: 10.1074/jbc.M505804200. Epub 2005 Oct 3. PMID: 16204252.

61. Matsumoto S, Shamloo M, Matsumoto E, Isshiki A, Wieloch T. Protein kinaseC-gamma and calcium/calmodulin-dependent protein kinase II-alpha are Persistently translocated to cell membranes of the rat brain during and after middle cerebral artery occlusion. J Cereb Blood Flow Metab. 2004 Jan;24(1):54-61. doi: 10.1097/01.WCB.0000095920.70924.F5. PMID: 14688616.

62. Mattiasson G, Shamloo M, Gido G, Mathi K, Tomasevic G, Yi S, Warden CH, Castilho RF, Melcher T, Gonzalez-Zulueta M, Nikolich K, Wieloch T. Uncoupling protein-2 prevents neuronal death and diminishes brain dysfunction after stroke and brain trauma. Nat Med. 2003 Aug;9(8):1062-8. doi: 10.1038/nm903. Epub 2003 Jul 13. PMID: 12858170.

63. Matsumoto S, Shamloo M, Isshiki A, Wieloch T. Persistent phosphorylation of synaptic proteins following middle cerebral artery occlusion. J Cereb Blood Flow Metab. 2002 Sep;22(9):1107-13. doi: 10.1097/00004647-200209000 00008. PMID:12218416.

64. Shamloo M, Kamme F, Wieloch T. Subcellular distribution and autophosphorylation of calcium/calmodulin-dependent protein kinase II-alpha in rat hippocampus in a model of ischemic tolerance. Neuroscience. 2000;96(4):665-74. doi: 10.1016/s0306-4522(99)00586-2. PMID: 10727785.

65. Shamloo M, Rytter A, Wieloch T. Activation of the extracellular signal-regulated protein kinase cascade in the hippocampal CA1 region in a rat model of global cerebral ischemic preconditioning. Neuroscience. 1999;93(1):81-8. doi:10.1016/s0306-4522(99)00137-2. PMID: 10430472.

66. Tomasevic G, Shamloo M, Israeli D, Wieloch T. Activation of p53 and its target genes p21(WAF1/Cip1) and PAG608/Wig-1 in ischemic preconditioning. Brain Res Mol Brain Res. 1999 Jul 5;70(2):304-13. doi:10.1016/s0169-328x(99)00146-1. PMID: 10407180.

67. Shamloo M, Wieloch T. Rapid decline in protein kinase Cgamma levels in the synaptosomal fraction of rat hippocampus after ischemic preconditioning. Neuroreport. 1999 Apr 6;10(5):931-5. doi: 10.1097/00001756199904060-00007.PMID: 10321462.

68. Shamloo M, Wieloch T. Changes in protein tyrosine phosphorylation in the rat brain after cerebral ischemia in a model of ischemic tolerance. J Cereb Blood Flow Metab. 1999 Feb;19(2):173-83. doi: 10.1097/00004647 199902000-00009. PMID:10027773.

69. Rundén E, Seglen PO, Haug FM, Ottersen OP, Wieloch T, Shamloo M, Laake JH. Regional selective neuronal degeneration after protein phosphatase inhibition in hippocampal slice cultures: evidence for a MAP kinase-dependent mechanism. J Neurosci. 1998 Sep 15;18(18):7296-305. doi: 10.1523/JNEUROSCI.18-18-07296.1998. PMID: 9736650; PMCID: PMC6793243.

70. Khaspekov L, Shamloo M, Victorov I, Wieloch T. Sublethal in vitro glucose-oxygen deprivation protects cultured hippocampal neurons against a subsequent severe insult. Neuroreport. 1998 May 11;9(7):1273-6. doi: 10.1097/00001756-199805110-00003. PMID: 9631411.

71. Li PA, Kristián T, Shamloo M, Siesjö K. Effects of preischemic hyperglycemia on brain damage incurred by rats subjected to 2.5 or 5 minutes of forebrain ischemia. Stroke. 1996 Sep;27(9):1592-601; discussion 1601-2. doi: 10.1161/01.str.27.9.1592. PMID: 8784135.

72. Li PA, Shamloo M, Katsura Ki, Smith ML, Siesjö BK. Critical values for plasma glucose in aggravating ischaemic brain damage: correlation to extracellular pH. Neurobiol Dis. 1995 Apr;2(2):97-108. doi:10.1006/nbdi.1995.0010. PMID: 8980013.

73. Li PA, Kristián T, Katsura K, Shamloo M, Siesjö BK. The influence of insulin-induced hypoglycemia on the calcium transients accompanying reversible forebrain ischemia in the rat. Exp Brain Res. 1995;105(3):363-9. doi:10.1007/BF00233036. PMID: 7498390.

74. Li PA, Shamloo M, Smith ML, Katsura K, Siesjö BK. The influence of plasma glucose concentrations on ischemic brain damage is a threshold function. Neurosci Lett. 1994 Aug 15;177(1-2):63-5. doi: 10.1016/0304 3940(94)900450. PMID: 7824184.

Progress Report Publications:

1. Evans AK, Saw NL, Woods CE, Vidano LM, Blumenfeld S, Lam RK, Chu EK, Reading C, Shamloo M. Impact of high-fat diet on cognitive behavior and central and systemic inflammation with aging and sex differences in mice. Brain Behav Immun. 2024. Epub 20240224. doi: 10.1016/j.bbi.2024.02.025. PubMed PMID: 38408498.
2. Shamloo S, Defensor E, Ciari P, Ogawa G, Vidano L, Lin JS, Fortkort JA, Shamloo M, Barron AE. The anti-inflammatory effects of photobiomodulation are mediated by cytokines: Evidence from a mouse model of inflammation. Front Neurosci. 2023;17:1150156. Epub 20230406. doi: 10.3389/fnins.2023.1150156. PubMed PMID: 37090796; PMCID: PMC10115964.
3. Matt RA, Martin RS, Evans AK, Gever JR, Vargas GA, Shamloo M, Ford AP. Locus Coeruleus and Noradrenergic Pharmacology in Neurodegenerative Disease. Handb Exp Pharmacol. 2023. Epub 20230727. doi: 10.1007/164_2023_677. PubMed PMID: 37495851.
4. Bowen ER, DiGiacomo P, Fraser HP, Guttenplan K, Smith BAH, Heberling ML, Vidano L, Shah N, Shamloo M, Wilson JL, Grimes KV. Beta-2 adrenergic receptor agonism alters astrocyte phagocytic activity and has potential applications to psychiatric disease. Discov

Ment Health. 2023;3(1):27. Epub 20231130. doi: 10.1007/s44192-023-00050-5. PubMed PMID: 38036718; PMCID: PMC10689618.

5. Revah O, Gore F, Kelley KW, Andersen J, Sakai N, Chen X, Li MY, Birey F, Yang X, Saw NL, Baker SW, Amin ND, Kulkarni S, Mudipalli R, Cui B, Nishino S, Grant GA, Knowles JK, Shamloo M, Huguenard JR, Deisseroth K, Pasca SP. Maturation and circuit integration of transplanted human cortical organoids. Nature. 2022;610(7931):319-26. Epub 20221012. doi: 10.1038/s41586-022-05277-w. PubMed PMID: 36224417; PMCID: PMC9556304.
6. Lam DD, Williams RH, Lujan E, Tanabe K, Huber G, Saw NL, Merl-Pham J, Salminen AV, Lohse D, Spendiff S, Plastini MJ, Zech M, Lochmuller H, Geerlof A, Hauck SM, Shamloo M, Wernig M, Winkelmann J. Collagen VI Regulates Motor Circuit Plasticity and Motor Performance by Cannabinoid Modulation. J Neurosci. 2022;42(8):1557-73. Epub 20211227. doi: 10.1523/JNEUROSCI.0962-21.2021. PubMed PMID: 34965974; PMCID: PMC8883874.
7. Evans AK, Defensor E, Shamloo M. Selective Vulnerability of the Locus Coeruleus Noradrenergic System and its Role in Modulation of Neuroinflammation, Cognition, and Neurodegeneration. Front Pharmacol. 2022;13:1030609. Epub 20221130. doi: 10.3389/fphar.2022.1030609. PubMed PMID: 36532725; PMCID: PMC9748190.
8. Aloul KM, Nielsen JE, Defensor EB, Lin JS, Fortkort JA, Shamloo M, Cirillo JD, Gombart AF, Barron AE. Upregulating Human Cathelicidin Antimicrobial Peptide LL-37 Expression May Prevent Severe COVID-19 Inflammatory Responses and Reduce Microthrombosis. Front Immunol. 2022;13:880961. Epub 20220512. doi: 10.3389/fimmu.2022.880961. PubMed PMID: 35634307; PMCID: PMC9134243.
9. Wawro AM, Gajera CR, Baker SA, Lesniak RK, Montine KS, Fischer CR, Saw NL, Shamloo M, Montine TJ. Enantiomers of 4-aminopentanoic acid act as false GABAergic neurotransmitters and impact mouse behavior. J Neurochem. 2021;158(5):1074-82. Epub 20210802. doi: 10.1111/jnc.15474. PubMed PMID: 34273193.
10. Wawro AM, Gajera CR, Baker SA, Lesniak RK, Fischer CR, Saw NL, Shamloo M, Montine TJ. Enantiomers of 2-methylglutamate and 2-methylglutamine selectively impact mouse brain metabolism and behavior. Sci Rep. 2021;11(1):8138. Epub 20210414. doi: 10.1038/s41598-021-87569-1. PubMed PMID: 33854131; PMCID: PMC8047011.
11. Evans AK, Park HH, Saw NL, Singhal K, Ogawa G, Leib RD, Shamloo M. Age-related neuroinflammation and pathology in the locus coeruleus and hippocampus: beta-adrenergic antagonists exacerbate impairment of learning and memory in aged mice. Neurobiol Aging. 2021;106:241-56. Epub 20210620. doi: 10.1016/j.neurobiolaging.2021.06.012. PubMed PMID: 34320462; PMCID: PMC8419102.
12. De Miguel Z, Khoury N, Betley MJ, Lehallier B, Willoughby D, Olsson N, Yang AC, Hahn O, Lu N, Vest RT, Bonanno LN, Yerra L, Zhang L, Saw NL, Fairchild JK, Lee D, Zhang H, McAlpine PL, Contrepois K, Shamloo M, Elias JE, Rando TA, Wyss-Coray T. Exercise plasma boosts memory and dampens brain inflammation via clusterin. Nature. 2021;600(7889):494-9. Epub 20211208. doi: 10.1038/s41586-021-04183-x. PubMed PMID: 34880498; PMCID: PMC9721468.
13. Tsai RM, Miller Z, Koestler M, Rojas JC, Ljubenkov PA, Rosen HJ, Rabinovici GD, Fagan AM, Cobigo Y, Brown JA, Jung JI, Hare E, Geldmacher DS, Natelson-Love M, McKinley EC, Luong PN, Chuu EL, Powers R, Mumford P, Wolf A, Wang P, Shamloo M, Miller BL, Roberson ED, Boxer AL. Reactions to Multiple Ascending Doses of the Microtubule

Stabilizer TPI-287 in Patients With Alzheimer Disease, Progressive Supranuclear Palsy, and Corticobasal Syndrome: A Randomized Clinical Trial. JAMA Neurol. 2020;77(2):215-24. doi: 10.1001/jamaneurol.2019.3812. PubMed PMID: 31710340; PMCID: PMC6865783.

14. Evans AK, Ardestani PM, Yi B, Park HH, Lam RK, Shamloo M. Beta-adrenergic receptor antagonism is proinflammatory and exacerbates neuroinflammation in a mouse model of Alzheimer's Disease. Neurobiol Dis. 2020;146:105089. Epub 20200922. doi: 10.1016/j.nbd.2020.105089. PubMed PMID: 32971233; PMCID: PMC7686098.
15. Liu Q, Liang X, Wang Q, Wilson EN, Lam R, Wang J, Kong W, Tsai C, Pan T, Larkin PB, Shamloo M, Andreasson KI. PGE(2) signaling via the neuronal EP2 receptor increases injury in a model of cerebral ischemia. Proc Natl Acad Sci U S A. 2019;116(20):10019-24. Epub 20190429. doi: 10.1073/pnas.1818544116. PubMed PMID: 31036664; PMCID: PMC6525498.
16. Liu Q, Johnson EM, Lam RK, Wang Q, Bo Ye H, Wilson EN, Minhas PS, Liu L, Swarovski MS, Tran S, Wang J, Mehta SS, Yang X, Rabinowitz JD, Yang SS, Shamloo M, Mueller C, James ML, Andreasson KI. Peripheral TREM1 responses to brain and intestinal immunogens amplify stroke severity. Nat Immunol. 2019;20(8):1023-34. Epub 20190701. doi: 10.1038/s41590-019-0421-2. PubMed PMID: 31263278; PMCID: PMC6778967.
17. Djurisic M, Brott BK, Saw NL, Shamloo M, Shatz CJ. Activity-dependent modulation of hippocampal synaptic plasticity via PirB and endocannabinoids. Mol Psychiatry. 2019;24(8):1206-19. Epub 20180418. doi: 10.1038/s41380-018-0034-4. PubMed PMID: 29670176; PMCID: PMC6372352.
18. Bieri G, Brahic M, Bousset L, Couthouis J, Kramer NJ, Ma R, Nakayama L, Monbureau M, Defensor E, Schule B, Shamloo M, Melki R, Gitler AD. LRRK2 modifies alpha-syn pathology and spread in mouse models and human neurons. Acta Neuropathol. 2019;137(6):961-80. Epub 20190329. doi: 10.1007/s00401-019-01995-0. PubMed PMID: 30927072; PMCID: PMC6531417.
19. Ravina K, Briggs DI, Kislal S, Warraich Z, Nguyen T, Lam RK, Zarembinski TI, Shamloo M. Intracerebral Delivery of Brain-Derived Neurotrophic Factor Using HyStem((R))-C Hydrogel Implants Improves Functional Recovery and Reduces Neuroinflammation in a Rat Model of Ischemic Stroke. Int J Mol Sci. 2018;19(12). Epub 20181128. doi: 10.3390/ijms19123782. PubMed PMID: 30486515; PMCID: PMC6321015.
20. Kornfeld OS, Qvit N, Haileselassie B, Shamloo M, Bernardi P, Mochly-Rosen D. Interaction of mitochondrial fission factor with dynamin related protein 1 governs physiological mitochondrial function in vivo. Sci Rep. 2018;8(1):14034. Epub 20180919. doi: 10.1038/s41598-018-32228-1. PubMed PMID: 30232469; PMCID: PMC6145916.
21. Joshi AU, Saw NL, Vogel H, Cunnigham AD, Shamloo M, Mochly-Rosen D. Inhibition of Drp1/Fis1 interaction slows progression of amyotrophic lateral sclerosis. EMBO Mol Med. 2018;10(3). doi: 10.15252/emmm.201708166. PubMed PMID: 29335339; PMCID: PMC5840540.
22. Joshi AU, Saw NL, Shamloo M, Mochly-Rosen D. Drp1/Fis1 interaction mediates mitochondrial dysfunction, bioenergetic failure and cognitive decline in Alzheimer's disease. Oncotarget. 2018;9(5):6128-43. Epub 20171222. doi: 10.18632/oncotarget.23640. PubMed PMID: 29464060; PMCID: PMC5814200.
23. Huang WH, Wang DC, Allen WE, Klope M, Hu H, Shamloo M, Luo L. Early adolescent Rai1 reactivation reverses transcriptional and social interaction deficits in a mouse model

of Smith-Magenis syndrome. Proc Natl Acad Sci U S A. 2018;115(42):10744-9. Epub 20181001. doi: 10.1073/pnas.1806796115. PubMed PMID: 30275311; PMCID: PMC6196530.

24. Yi B, Sahn JJ, Ardestani PM, Evans AK, Scott LL, Chan JZ, Iyer S, Crisp A, Zuniga G, Pierce JT, Martin SF, Shamloo M. Small molecule modulator of sigma 2 receptor is neuroprotective and reduces cognitive deficits and neuroinflammation in experimental models of Alzheimer's disease. J Neurochem. 2017;140(4):561-75. doi: 10.1111/jnc.13917. PubMed PMID: 27926996; PMCID: PMC5312682.
25. Yi B, Jahangir A, Evans AK, Briggs D, Ravina K, Ernest J, Farimani AB, Sun W, Rajadas J, Green M, Feinberg EN, Pande VS, Shamloo M. Discovery of novel brain permeable and G protein-biased beta-1 adrenergic receptor partial agonists for the treatment of neurocognitive disorders. PLoS One. 2017;12(7):e0180319. Epub 20170726. doi: 10.1371/journal.pone.0180319. PubMed PMID: 28746336; PMCID: PMC5529018.
26. Sha SJ, Miller ZA, Min SW, Zhou Y, Brown J, Mitic LL, Karydas A, Koestler M, Tsai R, Corbetta-Rastelli C, Lin S, Hare E, Fields S, Fleischmann KE, Powers R, Fitch R, Martens LH, Shamloo M, Fagan AM, Farese RV, Jr., Pearlman R, Seeley W, Miller BL, Gan L, Boxer AL. An 8-week, open-label, dose-finding study of nimodipine for the treatment of progranulin insufficiency from GRN gene mutations. Alzheimers Dement (N Y). 2017;3(4):507-12. Epub 20170912. doi: 10.1016/j.trci.2017.08.002. PubMed PMID: 29124108; PMCID: PMC5671622.
27. Briggs DI, Defensor E, Memar Ardestani P, Yi B, Halpain M, Seabrook G, Shamloo M. Role of Endoplasmic Reticulum Stress in Learning and Memory Impairment and Alzheimer's Disease-Like Neuropathology in the PS19 and APP(Swe) Mouse Models of Tauopathy and Amyloidosis. eNeuro. 2017;4(4). Epub 20170714. doi: 10.1523/ENEURO.0025-17.2017. PubMed PMID: 28721361; PMCID: PMC5510086.
28. Ardestani PM, Evans AK, Yi B, Nguyen T, Coutellier L, Shamloo M. Modulation of neuroinflammation and pathology in the 5XFAD mouse model of Alzheimer's disease using a biased and selective beta-1 adrenergic receptor partial agonist. Neuropharmacology. 2017;116:371-86. Epub 20170113. doi: 10.1016/j.neuropharm.2017.01.010. PubMed PMID: 28089846; PMCID: PMC5385159.

Review Articles: (1 total)

1. **Shamloo, M.**, Belichenko, P.V., Mobley, W.C. Comprehensive Behavioral Assays to Enhance Phenotype to Genotype Linkages and Therapeutic Screening in Mouse Models of Down Syndrome. *Future Neurology* Jul;5(4):467-71, 2010.

Book Chapters: (2 total)

1. Wieloch T, Hu BR, **Shamloo, M.** Aberrant Cell Signaling in the Postischemic Brain: An Integrated View. In: Welch KMA, Caplan, L.R., Reis, D.J., Siesjö, B.K., Weir, B., eds. Primer on Cerebrovascular Diseases. San Diego: Academic Press, 1997. pp. 227-230.
2. **Shamloo, M.**, and Wieloch T. Preconditioning Depresses Excitatory Cell Signaling Following the Second Lethal Insult. In: Ito U, et al, eds. Maturation Phenomena in Cerebral Ischemia II. Heidelberg: Springer-Verlag, 1997. pp. 77-84.

Book: (1 total)

1. **Shamloo, M.** Ischemic Tolerance and Cell Signaling in the Rat Brain, ISBN 91-628-3715-X, 1999 (*Ph.D. thesis published as an independent book with ISBN number*)

Invited Presentations and Posters (20 shown here)

2016 "Inhibition of Sig2R/PGRMC: A potential strategy for treating Alzheimer's Disease," Society for Neuroscience 2016, San Diego. Talk.
2016 "Beta1 adrenergic receptors modulate neurocognitive function, neuroinflammation and pathology in a mouse model of Alzheimer's Disease" Society for Neuroscience 2016, San Diego. Poster.
2016 "Role of β-adrenoreceptor partial agonist in pathophysiology and recovery of ischemic stroke" Society for Neuroscience 2016, San Diego. Poster.
2016 Npas4 as a Marker of Recent Neuronal Activity, Winter Conference on Neural Plasticity (WCNP), Lahaina, HI.
2015 "Targeting β_1-Adrenergic receptor as a novel therapeutic approach for treatment of Alzeimer's disease." Brian Disorders and Therapeutics, London United kingdom. Talk.
2015 "Development of novel therapeutics targeting Sig2R/PGRMC1 for Alzheimer's Disease, "Society for Neuroscience 2015, Chicago, IL. Poster.
2015 "A small molecule p75 neurotrophin receptor ligand reduces Huntington's Disease phenotypes in R6/2 and BACHD mice ", Society for Neuroscience 2015, Chicago, IL. Poster.
2015 "Chronic low level beta1-adrenergic receptor activation decreases amyloid beta, modulates the neuroimmune response and improves neurocognitive function in two models of Alzheimer's disease ", Society for Neuroscience 2015, Chicago, IL. Poster.
2014 "Effects of TPI 287, a novel taxoid, on a transgenic mouse model of Alzheimer's disease ", Society for Neuroscience 2014, Washington. Poster.
2014 "Role of β1-adrenergic signaling in Alzheimer's disease (AD) ", Society for Neuroscience 2014, Washington. Poster.
2014 "Aberrant Subcellular Distribution of CREB/PCREB in Alzheimer's disease ", Society for Neuroscience 2014, Washington. Poster.
2014 "Cathepsin s: a novel therapeutic target for Alzheimer's disease," Society for Neuroscience 2014, Washington. Poster.
2014 "Passive immunization with the anti-Aβ oligomer antibody ACU-3B3 improves behavioral deficits in hAPPSL transgenic mice ", Society for Neuroscience 2014, Washington. Poster.
2014 Targeting β_1-Adrenergic receptor as a novel therapeutic approach for treatment of Alzheimer's disease Drug Discovery and Therapy World Congress, Boston, MA. Talk.
2012 "Implication of the transcription factor Npas4 in cognitive and social functions" International Behavioral Neuroscience Society, Kailua-Kona, Hawaii**.** Talk.
2012 "Activation of β_1 -Adrenergic Receptor as a Potential Memory Enhancement Strategy in Neuro Cognitive Disorders". Neurobiology Grand Rounds, University of Lund, Sweden, Wallenberg Neuroscience Research Center. Talk.
2011 "Implication of β_1-Adrenergic Receptor in Social Recognition." Cell Symposia: Autism Spectrum Disorders: From Mechanisms to Therapies, Arlington, Virginia. Poster.

2011 "Xamoterol Rescues Memory Deficit in Mouse Model of Down Syndrome by Activation of β_1-Adrenergic Receptor." 8th IBRO (International Brain Research Organization) World Congress of Neuroscience, Florence, Italy.
2011 "Xamoterol Rescues Memory Deficit in Mouse Model of Down Syndrome by Activation of β_1-Adrenergic Receptor." International Behavioral Neuroscience Society, Steamboat Springs, Colorado. Talk.
2008 "Cognitive Testing in Animal Models of Huntington's Disease." CHDI Foundation, Inc., Los Angeles, California.

F. PATENTS

*The patent listed below is "Active" in the US and "Pending" in other regions.

1. Evans AK, Green MJ, Jahangir A, Shamloo M, Yi B, inventors; The Board of Trustees of the Leland Stanford Junior University, assignee. Adrenergic Receptor Modulating Compounds and Methods of Using the Same, US11173144B2. November 16 2021.

2. Evans AK, Green MJ, Jahangir A, Shamloo M, Yi B, inventors; The Board of Trustees of the Leland Stanford Junior University, assignee. Adrenergic Receptor Modulating Compounds and Methods of Using the Same, EP17796976.3. May 12 2017.

3. Evans AK, Green MJ, Jahangir A, Shamloo M, Yi B, inventors; The Board of Trustees of the Leland Stanford Junior University, assignee. Adrenergic Receptor Modulating Compounds and Methods of Using the Same, CN201780038617.4A. May 12 2017.

4. Evans AK, Green MJ, Jahangir A, Shamloo M, Yi B, inventors; The Board of Trustees of the Leland Stanford Junior University, assignee. Adrenergic Receptor Modulating Compounds and Methods of Using the Same, MX2018013812A. May 12 2017.

5. Evans AK, Green MJ, Jahangir A, Shamloo M, Yi B, inventors; The Board of Trustees of the Leland Stanford Junior University, assignee. Adrenergic Receptor Modulating Compounds and Methods of Using the Same, KR1020187036246A. May 12 2017.

6. Evans AK, Green MJ, Jahangir A, Shamloo M, Yi B, inventors; The Board of Trustees of the Leland Stanford Junior University, assignee. Adrenergic Receptor Modulating Compounds and Methods of Using the Same, JP2018559812A. May 12 2017.

7. Evans AK, Green MJ, Jahangir A, Shamloo M, Yi B, inventors; The Board of Trustees of the Leland Stanford Junior University, assignee. Adrenergic Receptor Modulating Compounds and Methods of Using the Same, MA044994A. May 12 2017.
8. Evans AK, Green MJ, Jahangir A, Shamloo M, Yi B, inventors; The Board of Trustees of the Leland Stanford Junior University, assignee. Adrenergic Receptor Modulating Compounds and Methods of Using the Same, WO2017197324A1. May 12 2017.